$3.21
+0.05 (+1.58%)
Open$3.29
Previous Close$3.16
Day High$3.39
Day Low$3.17
52W High$6.62
52W Low$2.98
Volume—
Avg Volume187.7K
Market Cap70.14M
P/E Ratio—
EPS$-1.07
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,048.0% upside
Current
$3.21
$3.21
Target
$36.85
$36.85
$27.29
$36.85 avg
$45.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.19M | 21.48M | 20.04M |
| Net Income | -27,212,633 | -5,165,355 | -3,853,498 |
| Profit Margin | -267.1% | -24.1% | -19.2% |
| EBITDA | -28,881,383 | -6,655,427 | -5,995,002 |
| Free Cash Flow | — | -3,535,951 | -2,421,928 |
| Rev Growth | — | -8.7% | +0.8% |
| Debt/Equity | — | 0.24 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |